A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers

Summary

This is an open-label, multicentre, randomized, Phase II study and will be conducted with co-primary objectives of the study are to assess the efficacy of AUR109, as measured by ORR and safety / tolerability at three different dose levels of the study drug in three cancer indications i.e., colorectal, ovarian cancer and renal cancer.

Timeline

Start

2024-11-09

Primary completion

2026-02-01

Completion

2026-02-01

Outcome

Outcome not reported

Stopped (Enrollment): “Patient recruitment problems.”

Drugs

Indications